Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China - Lu Li; Shilei Yang; Fengqi Fang; Li Tian; Ying He; Jia Li; Yanwei Chen; Deshi Dong (Frontiers in Pharmacology)